Managing Metastatic Prostate Cancer In Your Urological Oncology Practice

K.C. Balaji, MD Chief of Urology, W.G. (Bill) Hefner VA Medical Center, Salisbury, North Carolina Professor of Urology and Cancer Biology, Wake Forest University School of Medicine, Winston Salem, North Carolina Department of Urology, Cancer Biology, Institute of Regenerative Medicine Wake Forest University School of Medicine, W.G. (Bill) Hefner VA Medical Center

Introduction.- Pathophysiology of Castration-Resistant Prostate Cancer.- Androgen Receptor Signaling in Castration Resistant Prostate Cancer.- Non-Androgen Signaling Pathways in Castration-Resistant Prostate Cancer.- Predictive Models in Castration Resistant Prostate Cancer.- Docetaxel in Advanced and Castration Resistant Prostate Cancer.- Combination Treatment Strategies with Docetaxel in Patients with Metastatic Prostate.- Cancer Vaccines in Castration Resistant Prostate Cancer - An evolution in design.- Abiraterone for the treatment of mCRPC.- Enzalutamide in Metastatic Castration Resistant Prostate Cancer.- Radium-223 in Metastatic Castrate Resistant Prostate Cancer.- Cabazitaxel for the Treatment of Prostate Cancer.- Sequencing Therapies in Metastatic Castration Resistant Prostate Cancer.- Bone Preservation Strategies for Men on Androgen Deprivation Therapy.- Novel Therapies in Castration-Resistant Prostate Cancer.